Abstract
The Janus kinases (JAKs) enzymes are a family of cytosolic tyrosine kinases that are associated with membrane receptors and play a critical role in the rapid transduction of signals from cell surface to the nucleus. There are four different tyrosine kinases (Tyk2, Jak1, Jak2, Jak3) that share significant structural homology with each other. Binding of cytokines or growth factors to their cognate receptor activate JAK kinases, which in turn mediate the subsequent tyrosine phosphorylation of STAT proteins. Phosphorylated STAT proteins form dimers, translocate to the nucleus, and bind to specific DNA elements to induce or modulate expression of target genes. Aberrant activation of JAK kinases has been implicated in many hematological malignancies and carcinomas. There is also accumulating evidence that constitutive activation of different Jaks and Stats mediate neoplastic transformation and promote abnormal cell proliferation in various malignancies. This review will discuss the role of various Jak-kinase dependent signal transduction pathways in malignancies as well as therapeutic implications of the recent advances in the field.
Keywords: Janus kinase, signal transducer and activator of transcription, suppressors of cytokine signaling, cytokines, signal transduction pathways
Current Enzyme Inhibition
Title: JAK Family of Tyrosine Kinases: Its Functions and Alterations in Human Cancer
Volume: 2 Issue: 2
Author(s): Shahab Uddin, Azhar R. Hussain and Khawla S. Al-Kuraya
Affiliation:
Keywords: Janus kinase, signal transducer and activator of transcription, suppressors of cytokine signaling, cytokines, signal transduction pathways
Abstract: The Janus kinases (JAKs) enzymes are a family of cytosolic tyrosine kinases that are associated with membrane receptors and play a critical role in the rapid transduction of signals from cell surface to the nucleus. There are four different tyrosine kinases (Tyk2, Jak1, Jak2, Jak3) that share significant structural homology with each other. Binding of cytokines or growth factors to their cognate receptor activate JAK kinases, which in turn mediate the subsequent tyrosine phosphorylation of STAT proteins. Phosphorylated STAT proteins form dimers, translocate to the nucleus, and bind to specific DNA elements to induce or modulate expression of target genes. Aberrant activation of JAK kinases has been implicated in many hematological malignancies and carcinomas. There is also accumulating evidence that constitutive activation of different Jaks and Stats mediate neoplastic transformation and promote abnormal cell proliferation in various malignancies. This review will discuss the role of various Jak-kinase dependent signal transduction pathways in malignancies as well as therapeutic implications of the recent advances in the field.
Export Options
About this article
Cite this article as:
Uddin Shahab, Hussain R. Azhar and Al-Kuraya S. Khawla, JAK Family of Tyrosine Kinases: Its Functions and Alterations in Human Cancer, Current Enzyme Inhibition 2006; 2 (2) . https://dx.doi.org/10.2174/157340806776818766
DOI https://dx.doi.org/10.2174/157340806776818766 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Demographic and Clinical Evaluation of Patients with Pancreatic Cancer in Mashhad University of Medical Sciences During 2002-2013
Current Cancer Therapy Reviews State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents
Current Pharmaceutical Analysis Editorial [Hot Topic: New Perspectives in the Treatment of Hematological Malignancies (Guest Editor: Masahiro Kizaki)]
Current Pharmaceutical Biotechnology Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Epigenetic MicroRNA Regulation of Multiple Chromatin Functions: A Perspective in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety
Recent Patents on Anti-Cancer Drug Discovery HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Radiation Therapy in the Management of Lung Cancer
Current Respiratory Medicine Reviews Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings
Current Pharmaceutical Design The Cytoskeleton as a Therapeutic Target in Childhood Acute Leukemia:Obstacles and Opportunities
Current Drug Targets The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets Issues in the Psychiatric Screening of Cancer Patients
Current Psychiatry Reviews Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry